[
  {
    "ts": "2025-08-08T03:48:27+00:00",
    "headline": "Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral",
    "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On July 25, Baird analyst Michael Ha reduced the price target on the company’s stock to $297 from $492, while keeping a “Neutral” rating, as reported by The Fly. This comes as part of an update on the managed […]",
    "url": "https://finance.yahoo.com/news/baird-reduces-pt-elevance-health-034827146.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "6c5a7507-6ea0-3ac1-86bd-b508e9f83220",
      "content": {
        "id": "6c5a7507-6ea0-3ac1-86bd-b508e9f83220",
        "contentType": "STORY",
        "title": "Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral",
        "description": "",
        "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On July 25, Baird analyst Michael Ha reduced the price target on the company’s stock to $297 from $492, while keeping a “Neutral” rating, as reported by The Fly. This comes as part of an update on the managed […]",
        "pubDate": "2025-08-08T03:48:27Z",
        "displayTime": "2025-08-08T03:48:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d7a36b6d509f8a05b8ab87b898f5eeb5",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XMDnXzEPOHFrZWTayj9s.w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d7a36b6d509f8a05b8ab87b898f5eeb5.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G84s0HL9z253EyKlcmlKMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d7a36b6d509f8a05b8ab87b898f5eeb5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/baird-reduces-pt-elevance-health-034827146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/baird-reduces-pt-elevance-health-034827146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-08T03:47:57+00:00",
    "headline": "UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects",
    "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a ‘Buy’ rating on the stock and a $435 price target. The positive stance follows the healthcare company’s second-quarter results. The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. […]",
    "url": "https://finance.yahoo.com/news/ubs-affirms-elevance-health-elv-034757525.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "56c61066-3cef-3cb1-8b74-80c597de524c",
      "content": {
        "id": "56c61066-3cef-3cb1-8b74-80c597de524c",
        "contentType": "STORY",
        "title": "UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects",
        "description": "",
        "summary": "Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a ‘Buy’ rating on the stock and a $435 price target. The positive stance follows the healthcare company’s second-quarter results. The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. […]",
        "pubDate": "2025-08-08T03:47:57Z",
        "displayTime": "2025-08-08T03:47:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f90a941bb89e307321e6d78488d5cf55",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "UBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AX5qnlOT4ONm51toDhsMrg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f90a941bb89e307321e6d78488d5cf55.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.KvN6nvzz29v_YOQYIiYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f90a941bb89e307321e6d78488d5cf55.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ubs-affirms-elevance-health-elv-034757525.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ubs-affirms-elevance-health-elv-034757525.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]